In a preclinical study by Gallegos et al., [89Zr]-CD8 ImmunoPET was used in an orthotopic murine GBM model treated with a combination of oncolytic herpes simplex virus (oHSV) and anti-PD-1 therapy. Here, CD8A is linked to glioblastoma.